PT  - JOURNAL ARTICLE
AU  - Conaghan, Philip G.
AU  - McQueen, Fiona M.
AU  - Bird, Paul
AU  - Peterfy, Charles
AU  - Haavardsholm, Espen
AU  - Gandjbakhch, Frédérique
AU  - Eshed, Iris
AU  - Haugen, Ida K.
AU  - Lillegraven, Siri
AU  - Døhn, Uffe Møller
AU  - Ejbjerg, Bo
AU  - Foltz, Violaine
AU  - Coates, Laura
AU  - Bøyesen, Pernille
AU  - Hermann, Kay-Geert
AU  - Freeston, Jane
AU  - Lassere, Marissa
AU  - O’Connor, Philip
AU  - Emery, Paul
AU  - Genant, Harry
AU  - Østergaard, Mikkel
TI  - Update on the OMERACT Magnetic Resonance Imaging Task Force: Research and Future Directions
AID  - 10.3899/jrheum.131085
DP  - 2014 Feb 01
TA  - The Journal of Rheumatology
PG  - 383--385
VI  - 41
IP  - 2
4099  - http://www.jrheum.org/content/41/2/383.short
4100  - http://www.jrheum.org/content/41/2/383.full
SO  - J Rheumatol2014 Feb 01; 41
AB  - Magnetic resonance imaging (MRI) provides an important biomarker across a range of rheumatological diseases. At the Outcome Measures in Rheumatology (OMERACT) 11 meeting, the MRI task force continued its work of developing and improving the use of MRI outcomes for use in clinical trials. The breadth of pathology in the Rheumatoid Arthritis MRI Score has been strengthened with further work on the development of a joint space narrowing score, and a series of exercises presented at OMERACT 11 demonstrated good reliability and construct validity for this assessment. Understanding the importance of residual inflammation after RA treatment remains a major focus of the group’s work. Analyses were presented on defining the level of synovitis (using MRI scores of a single hand) that would predict absence of erosion progression. The development of the OMERACT Hand Osteoarthritis MRI score has continued with substantial work presented on its iterative development, including pathology definition, scaling, and subsequent reliability of the score. Optimizing the role of MRI as a robust biomarker and surrogate outcome remains a priority for this group.